Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma

Cancer Investigation

Volumn 27, Issue 8, 2009, Pages 851-856

  Harshman, Lauren C ^a   Kuo, Calvin J ^a   Wong, Bryan Y ^b   Vogelzang, Nicholas J ^b   Srinivas, Sandy ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEVADA CANCER INSTITUTE   (United States)

Author keywords

Bevacizumab; Erythropoiesis; Increased hemoglobin; Renal cell carcinoma; VEGF inhibition

Indexed keywords

BEVACIZUMAB; ERLOTINIB; HEMOGLOBIN; SORAFENIB; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CALIFORNIA; CARCINOMA, RENAL CELL; DATABASES AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HEMOGLOBINS; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEVADA; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70249099875     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900902744528     Document Type: Article

References (33)

1. Sukosd, F.; Kuroda, N.; Beothe, T.; Kaur, A.P.; Kovacs, G. Deletion of chromosome 3p14.2-p25 involving the vhl and fhit genes in conventional renal cell carcinoma. Cancer Res 2003, 63(2), 455-457.
2. Kim, W.; Kaelin, W.G., Jr. The von hippel-lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev 2003, 13(1), 55-60.
3. Escudier, B.; Eisner, T.; Staler, W.M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A.A.; Rolland, F.; Demkow, T.; Hutson, T.E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R.M. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2), 125-134.
4. Escudier, B.; Pluzanska, A.; Koralewski, P.; Ravaud, A.; Bracarda, S.; Szczylik, C.; Chevreau, C.; Filipek, M.; Melichar, B.; Bajetta, E.; Gorbunova, V.; Bay, J.O.; Bodrogi, I.; Jagiello-Gruszfeld, A.; Moore, N. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370(9605), 2103-2111.
5. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S.T.; Chen, I.; Bycott, P.W.; Baum, C.M.; Figlin, R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(2), 115-124. (Pubitemid 46089672)
6. Motzer, R.J.; Rini, B.I.; Bukowski, R.M.; Curti, B.D.; George, D.J.; Hudes, G.R.; Redman, B.G.; Margolin, K.A.; Merchan, J.R.; Wilding, G.; Ginsberg, M.S.; Bacik, J.; Kim, S.T.; Baum, C.M.; Michael-son, M.D. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295(21), 2516-2524. (Pubitemid 43854967)
7. Figlin, R.A.; Hutson, T.E.; Tomczak P.; Michaelson, M.D.; Bukowski, R.M.; Negrier, S., Huang, X., Kim, S.T.; Chen, I.; Motzer, R.J. Overall survival with sunitinib versus interferon (ifn)-alfa as first-line treatment of metastatic renal cell carcinoma (MRCC). ASCO Annual Meeting Proceedings 2008, Abstract 5024.
8. Bayer Pharmaceutical Sorafenib package insert, 2007.
9. Genentech Bevacizumab package insert March 2008.
10. Pfizer Sunitinib maleate package insert 2007.
11. Richard, S.; Croisille, L.; Yvart, J.; Casadeval, N.; Eschwege, P.; Aghakhani, N.; David, P.; Gaudric, A.; Scigalla, P.; Hermine, O. Paradoxical secondary polycythemia in von hippel-lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood 2002, 99(10), 3851-3853.
12. Alexandrescu, D.T.; McClure, R.; Farzanmehr, H.; Dasanu, C.A. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol 2008, 26(24), 4047-4048.
13. Wei, K.; Kuhnert, F.; Kuo, C.J. Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathways. J Mol Med 2008, 86(2), 161-169.
14. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; Gwyther, S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3), 205-216.
15. Bibb, J.L.; Lee, S.; Lu, D.; Lee, F. Increase in systolic (sbp) and decrease in diastolic blood pressure (dbp) may predict clinical benefit (cb) of bevacizumab (b) in patients (pts) with metastatic colorectal cancer (mcrc) treated with cytotoxic agents (ca). Gastrointestinal Cancers Symposium 2007, Abstract 450.
16. Friberg, G.; Kasza, K.; Vokes, E.E.; Kindler, H.L. Early hypertension (htn) as a potential pharmacodynamic (pd) marker for survival in pancreatic cancer (pc) patients (pts) treated with bevacizumab (b) and gemcitabine (g). ASCO Annual Meeting Proceedings. J Clin Oncol 2005, 23(16), Abstract 3020.
17. Rini, B.; Schiller, J.; Fruehauf, J.P.; Cohen, E.E.; Tarazi, J.C.; Rosbrook, B.; Ricart, A.D.; Olszanski, A.J.; Kim, S.; Spano, J. Association of diastolic blood pressure (dbp) > 90 mm hg with overall survival (os) in patients treated with axitinib (ag-013736). J Clin Oncol 2008, 26, Abstract 3543.
18. Tam, B.Y.; Wei, K.; Rudge, J.S.; Hoffman, J.; Holash, J.; Park, S.K.; Yuan, J.; Hefner, C.; Chartier, C.; Lee, J.S.; Jiang, S.; Niyak, N.R.; Kuypers, F.A.; Ma, L.; Sundram, U.; Wu, G.; Garcia, J.A.; Schrier, S.L.; Maher, J.J.; Johnson, R.S.; Yancopoulos, G.D.; Mulligan, R.C.; Kuo, C.J. Vegf modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006, 12 (7), 793-800.
19. Harshman, L.; Kuo, C.J.; Srinivas, S. Bevacizumab-associated ery-throcytosis in metastatic renal cell carcinoma (MRCC). American Society of Clinical Oncology Annual Meeting Proceedings 2008, Abstract 16096.
20. Cella, D.; Kallich, J.; McDermott, A.; Xu, X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004, 15(6), 979-986.
21. Canon, J.L.; Vansteenkiste, J.; Bodoky, G.; Mateos, M.V.; Bastit, L.; Ferreira, I.; Rossi, G.; Amado, R.G. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006, 98(4), 273-284. (Pubitemid 43264711)
22. Munugalavadla, V.; Kapur, R. Role of c-kit and erythropoietin receptor in erythropoiesis. Crit Rev Oncol Hematol 2005, 54(1), 63-75.
23. Abrams, T.J.; Lee, L.B.; Murray, L.J.; Pryer, N.K.; Cherrington, J.M. Su11248 inhibits kit and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003, 2(5), 471-478.
24. Motzer, R.J.; Michaelson, M.D.; Redman, B.G.; Hudes, G.R.; Wilding, G.; Figlin, R.A.; Ginsberg, M.S.; Kim, S.T.; Baum, C.M.; DePrimo, S.E.; Li, J.Z.; Bello, C.L.; Theuer, C.P.; George, D.J.; Rini, B.I. Activity of SU11248, a multitargeted inhibitor of vascular en-dothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24(1), 16-24.
25. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L.E.; Bollag, G.; Trail, P.A. Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the raf/mek/erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19), 7099-7109.
26. Motzer, R.J.; Mazumdar, M.; Bacik, J.; Berg, W.; Amsterdam, A.; Ferrara, J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17(8), 2530-2540.
27. Bukowski, R.M.; Kabbinavar, F.F.; Figlin, R.A.; Flaherty, K.; Srini-vas, S.; Vaishampayan, U.; Drabkin, H.A.; Dutcher, J.; Ryba, S.; Xia, Q.; Scappaticci, F.A.; McDermott, D. Randomized phase-II study of erlotinib combined with bevacizumab compared with be-vacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007, 25 (29), 4536-4541.
28. Yang, J.C.; Haworth, L.; Sherry, R.M.; Hwu, P.; Schwartzentruber, D.J.; Topalian, S.L.; Steinberg, S.M.; Chen, H.X.; Rosenberg, S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349(5), 427-434.
29. Choi, Y.M.; Shord, S.; Cuellar, S.; Villano, J. Examining ethnic differences for bevacizumab-induced hypertension and proteinuria. ASCO Annual Meeting Proceedings part I. J Clin Oncol 2007, 25, Abstract 21168.
30. Frey, M.K.; Olivera, N.; Bogomolniy, F.; Dao, F.; Borsu, L.; Konner, J.A.; Rizvi, N.A.; Barakat, R.R.; Dickler, M.N.; Levine, D.A. Wnk1 haplotypes and bevacizumab-induced hypertension. J Clin Oncol 2008, 26, Abstract 11003.
31. Fischer, C.; Carmeliet, P.; Conway, E.M. Vegf inhibitors make blood. Nat Med 2006, 12(7), 732-734.
32. Alexandre, I.; Billemont, B.; Meric, J.B.; Richard, S.; Rixe, O. Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma. J Clin Oncol 2009, 27, 472-473; author reply 3-4.
33. Van der Veldt, A.A.; Boven, E.; Vroling, L.; Broxterman, H.J.; van den Eertwegn, A.J.; Haanen, J.G. Sunitinib-induced hemoglobin changes are related to the dosing schedule. J Clin Oncol 2009; 27, 1339-1340; author reply 40-42.